Thoracoscopic Pleural Biopsy in Sohag University Hospital

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-01

Study Completion Date

2025-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to evaluate the diagnostic efficacy, safety, and clinical outcomes of thoracoscopic pleural biopsy in the management of pleural diseases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Visual Assessment vs ROSE in Diagnosing Pleural Effusion Using Medical Thoracoscopy

NCT07286045

Thoracoscopy Pleural Effusion Disorder

COMPLETED

Role of Ultrasound Guided Peripheral Thoracic Tumors

NCT04741958

Thoracic Neoplasms

COMPLETED NA

The Diagnostic Yield and Safety of Transbronchial Cryobiopsy in The Pulmonary Periphral Nodule

NCT04661956

Diagnosis Complication Rate

UNKNOWN NA

Role of B Mode and Color Doppler Sonography in Differentiation Between Pleural Neoplasm and Inflammatory Pleural Thickening in Correlation With CT Findings

NCT05701462

Pleural Thickening

UNKNOWN NA

Application of Transthoracic Shear-wave Ultrasound Elastography in Pleural Lesions

NCT04781894

Elasticity Imaging Techniques

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pleural Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Thoracoscopic pleural biopsy

This arm aims to evaluate the diagnostic efficacy, safety, and clinical outcomes of thoracoscopic pleural biopsy in the management of pleural diseases.

Group Type OTHER

thoracoscopic pleural biopsy.

Intervention Type PROCEDURE

This intervention aims to evaluate the diagnostic efficacy, safety, and clinical outcomes of thoracoscopic pleural biopsy in the management of pleural diseases.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

thoracoscopic pleural biopsy.

This intervention aims to evaluate the diagnostic efficacy, safety, and clinical outcomes of thoracoscopic pleural biopsy in the management of pleural diseases.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with suspected pleural disease who have been referred for thoracoscopic pleural biopsy
* Age: Adults aged 18 years and older
* Patients should have undergone necessary preoperative evaluations, including imaging studies (e.g., chest X-ray, CT scan) that indicate a need for biopsy.

Exclusion Criteria

* Contraindications to Thoracoscopic Biopsy: Patients with contraindications to thoracoscopic biopsy
* Infeasibility of Procedure: Patients with anatomical or physiological factors that make thoracoscopic biopsy technically unfeasible or unsafe (e.g., severe pleural adhesions or distorted anatomy).
* Alternative Diagnoses: Patients who have been definitively diagnosed with a condition that does not require thoracoscopic biopsy for further evaluation.
* Pregnancy: Pregnant women may be excluded due to potential risks to the fetus and the need for specific procedural considerations.
* Inability to Provide Consent: Patients who are unable to provide informed consent due to cognitive impairment, language barriers, or other reasons.
* Participation in Concurrent Studies: Patients currently participating in other clinical studies that could interfere with the outcomes of this study or affect their eligibility.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No